These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26546771)

  • 21. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom severity and exclusion from antidepressant efficacy trials.
    Zimmerman M; Posternak MA; Chelminski I
    J Clin Psychopharmacol; 2002 Dec; 22(6):610-4. PubMed ID: 12454561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variability in the substance use disorder exclusion criterion in antidepressant efficacy trials.
    Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
    J Affect Disord; 2016 Jul; 198():39-42. PubMed ID: 27002283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
    Thase ME; Mahableshwarkar AR; Dragheim M; Loft H; Vieta E
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J; Chen Y
    Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vortioxetine for the treatment of depression.
    Pearce EF; Murphy JA
    Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
    CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
    Jacobsen P; Zhong W; Xu R; Nomikos G
    J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.
    Zimmerman M; Multach M; Walsh E; Rosenstein LK; Gazarian D; Clark HL
    CNS Drugs; 2016 Mar; 30(3):185-91. PubMed ID: 26818632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
    Brignone M; Diamand F; Painchault C; Takyar S
    Curr Med Res Opin; 2016; 32(2):351-66. PubMed ID: 26637048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vortioxetine: a review of its use in major depressive disorder.
    Garnock-Jones KP
    CNS Drugs; 2014 Sep; 28(9):855-74. PubMed ID: 25145538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice.
    van der Lem R; van der Wee NJ; van Veen T; Zitman FG
    Psychol Med; 2011 Jul; 41(7):1353-63. PubMed ID: 21078225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy of major depression in late life: what is the role of new agents?
    Patel K; Abdool PS; Rajji TK; Mulsant BH
    Expert Opin Pharmacother; 2017 Apr; 18(6):599-609. PubMed ID: 28317392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of vortioxetine for the treatment of major depressive disorder.
    Dhir A; Sarvaiya J
    Expert Rev Neurother; 2014 Dec; 14(12):1349-63. PubMed ID: 25418918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Vortioxetine: a new antidepressant to treat depressive episodes].
    Colle R; Corruble E
    Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
    Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
    J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.